



# STIC Search Report

## Biotech-Chem Library

STIC Database Tracking Number: 177561

TO: Marcela Cordero Garcia  
Location: rem/3C35/3C18  
Art Unit: 1654  
Thursday, February 09, 2006

Case Serial Number: 10/699449

From: Mary Jane Ruhl  
Location: Biotech-Chem Library  
Remsen 1-A-62  
Phone: 571-272-2524

[maryjane.ruhl@uspto.gov](mailto:maryjane.ruhl@uspto.gov)

### Search Notes

Examiner Cordero Garcia,

Here are the results for your recent search request.

Please feel free to contact me if you have any questions about these results.

Thank you for using STIC services. We appreciate the opportunity to serve you.

Sincerely,

Mary Jane Ruhl  
Technical Information Specialist  
STIC  
Remsen 1-A-62  
Ext. 22524

17758

1187

From: Cordero Garcia, Marcela M.  
 Sent: Wednesday, January 25, 2006 11:27 AM  
 To: STIC-Biotech/ChemLib  
 Subject: Database Search Request, Serial Number: 10/699,449

RECEIVED  
 JAN 25 2006  
 STIC-BIOTECH/CHM  
 (STIC)

Requester:  
 MARCELA CORDERO GARCIA (P/1654)

Art Unit:  
 GROUP ART UNIT 1654

Employee Number:  
 80381

Office Location:  
 REM 03C35

Phone Number:  
 (571) 272-2939

Mailbox Number:  
 REM 3C18

Case serial number:  
 10/699,449

Class / Subclass(es):  
 514/1

Earliest Priority Filing Date:  
 10/31/03

Format preferred for results:  
 Paper

Search Topic Information:

Please search a method of separation of glycosylated proteins from unglycosylated proteins using a resin with a nucleophile bound to it.

Special Instructions and Other Comments:

Karla M. Bobotki  
 10/31/2003  
 Enrichment of Xapping  
 glycosylated proteins

\*\*\*\*\*  
 Searcher: \_\_\_\_\_  
 Searcher Phone: \_\_\_\_\_  
 Date Searcher Picked up: \_\_\_\_\_  
 Date completed: \_\_\_\_\_  
 Searcher Prep Time: \_\_\_\_\_  
 Online Time: \_\_\_\_\_

\*\*\*\*\*  
 Type of Search  
 NA# \_\_\_\_\_ AA# \_\_\_\_\_  
 S/L: \_\_\_\_\_ Oligomer: \_\_\_\_\_  
 Encode/Transl: \_\_\_\_\_  
 Structure #: \_\_\_\_\_ Text: \_\_\_\_\_  
 Inventor: \_\_\_\_\_ Litigation: \_\_\_\_\_

\*\*\*\*\*  
 Vendors and cost where applicable  
 STN: \_\_\_\_\_  
 DIALOG: \_\_\_\_\_  
 QUESTEL/ORBIT: \_\_\_\_\_  
 LEXIS/NEXIS: \_\_\_\_\_  
 SEQUENCE SYSTEM: \_\_\_\_\_  
 WWW/Internet: \_\_\_\_\_  
 Other (Specify): \_\_\_\_\_

=> d his ful

(FILE 'HOME' ENTERED AT 15:57:14 ON 09 FEB 2006)

FILE 'HCAPLUS' ENTERED AT 16:47:57 ON 09 FEB 2006

E ROBOTTI KARLA M/AU

L29 17 SEA ABB=ON ("ROBOTTI KARLA"/AU OR "ROBOTTI KARLA M"/AU OR  
"ROBOTTI KARLA MARIE"/AU)

L30 1 SEA ABB=ON L29 AND ?GLYCOSYLAT?(W)?PROTEIN?  
ANALYZE L30 1-1 CT : 5 TERMS

L32 124 SEA ABB=ON ?GLYCOSYLAT?(W)?PROTEIN? AND GEL?(W)?ELECTROPHORES?

L33 289 SEA ABB=ON ?GLYCOSYLAT?(W)?PROTEIN? AND (?SEPARAT? OR  
GEL?(W)?ELECTROPHORES?)

L34 1 SEA ABB=ON L33 AND ?RESIN?(3A)?NUCLEOPHIL?

L35 2 SEA ABB=ON L33 AND ?RESIN?

L36 2 SEA ABB=ON L34 OR L35

L37 1 SEA ABB=ON L36 AND (PRD<20031031 OR PD<20031031) *1st from CAplus*

FILE 'MEDLINE, BIOSIS, EMBASE, JAPIO, JICST-EPLUS' ENTERED AT 16:54:12 ON  
09 FEB 2006

L38 4 SEA ABB=ON L36

L39 2 DUP REMOV L38 (2 DUPLICATES REMOVED) *2nd from above d.b.'s*

FILE 'USPATFULL' ENTERED AT 16:54:55 ON 09 FEB 2006

L40 1440 SEA ABB=ON L36 AND (PRD<20031031 OR PD<20031031)

L41 1058 SEA ABB=ON L40 AND GEL?(W)?ELECTROPHOR?

L42 1023 SEA ABB=ON L41 AND ?CHROMATOG?

L43 650 SEA ABB=ON L42 AND (HPLC OR ?HIGH?(W)?PRESS?(W)?LIQUID?(W)?CHR  
OMATOG?)

L44 56 SEA ABB=ON L43 AND ?NUCLEOPHIL?

L45 0 SEA ABB=ON L44 AND ?TEST?(W)KIT?

L46 49 SEA ABB=ON L44 AND KIT?

L47 25 SEA ABB=ON L46 AND (?SOLID?(W)?PHASE?(W)?SYNTH?) *25 cts from  
USPatfull*

FILE HOME

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Feb 2006 VOL 144 ISS 7  
FILE LAST UPDATED: 8 Feb 2006 (20060208/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 FEB 2006 HIGHEST RN 873775-18-9  
DICTIONARY FILE UPDATES: 7 FEB 2006 HIGHEST RN 873775-18-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE MEDLINE

FILE LAST UPDATED: 8 FEB 2006 (20060208/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 will soon be available. For details  
on the 2005 reload, enter HELP RLOAD at an arrow prompt (=>).

See also:

<http://www.nlm.nih.gov/mesh/>  
[http://www.nlm.nih.gov/pubs/techbull/nd04/nd04\\_mesh.html](http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html)  
[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_med\\_data\\_changes.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html)  
[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_2006\\_MeSH.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html)

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the  
MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate

FILE BIOSIS

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT  
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 8 February 2006 (20060208/ED)

FILE EMBASE

FILE COVERS 1974 TO 2 Feb 2006 (20060202/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE JAPIO

FILE LAST UPDATED: 7 FEB 2006 <20060207/UP>

FILE COVERS APR 1973 TO SEPTEMBER 29, 2005

>>> GRAPHIC IMAGES AVAILABLE <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOT YET AVAILABLE IN THIS FILE.  
USE IPC7 FORMAT FOR SEARCHING THE IPC. WATCH THIS SPACE FOR FURTHER  
DEVELOPMENTS AND SEE OUR NEWS SECTION FOR FURTHER INFORMATION  
ABOUT THE IPC REFORM <<<

FILE JICST-EPLUS

FILE COVERS 1985 TO 7 FEB 2006 (20060207/ED)

THE JICST-EPLUS FILE HAS BEEN RELOADED TO REFLECT THE 1999 CONTROLLED TERM (/CT) THESAURUS RELOAD.

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 9 Feb 2006 (20060209/PD)

FILE LAST UPDATED: 9 Feb 2006 (20060209/ED)

HIGHEST GRANTED PATENT NUMBER: US6996845

HIGHEST APPLICATION PUBLICATION NUMBER: US2006031974

CA INDEXING IS CURRENT THROUGH 9 Feb 2006 (20060209/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 9 Feb 2006 (20060209/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2005

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2005

determined by NMR spectroscopy. The kinetic mechanism of the reaction was analyzed using the macrolide antibiotic lankamycin (LK) as substrate. The reaction operates via a compulsory order mechanism. This has been shown by steady-state kinetic studies and by isotopic exchange reactions at equilibrium. LK binds first to the enzyme, followed by UDP-glucose. A ternary complex is thus formed prior to transfer of glucose. UDP is then released, followed by the glycosylated lankamycin (GS-LK). A pH study of the reaction was performed to determine values for the molecular pK values, suggesting possible amino acid residues involved in the catalytic process.

L15 ANSWER 5 OF 6 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2005026572 EMBASE

TITLE: One-pot glycosylation (OPG) for the chemical synthesis of oligosaccharides.

AUTHOR: Yu B.; Yang Z.; Cao H.

CORPORATE SOURCE: B. Yu, State Key Laboratory of Bio-Organic, Shanghai Inst. of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Road, Shanghai 200032, China. byu@pub.sioc.ac.cn

SOURCE: Current Organic Chemistry, (2005) Vol. 9, No. 2, pp. 179-194. .

Refs: 63

ISSN: 1385-2728 CODEN: CORCFE

COUNTRY: Netherlands

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 029 Clinical Biochemistry

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 20050127

Last Updated on STN: 20050127

AB This review provides a comprehensive survey of the "one pot glycosylation" (OPG) strategy for the chemical synthesis of oligosaccharides, covering literatures from the first example reported by Kahne and Raghavan in 1993 through May 2003. The essence of the OPG is to distinguish the reactivity difference of a pair of the glycosylation donors or acceptors so as to carry out two glycosylation steps sequentially without purification of the first-step coupling product. Accordingly, the literature reports are grouped based on the major stereoelectronic factors causing the reactivity differences, those include the "armed-disarmed effect", "orthogonality of leaving groups", "distinguishable acceptors", and "the hybrid". "The hybrid" OPG procedure takes advantage of a combination of the reactivity disparity of a set of the armed-disarmed donors, orthogonal leaving groups, as well as acceptors so as to proceed three or more steps of glycosylation sequentially in one pot. Relevant conception and exploitation of the reactivity differences of the donors and acceptors in the synthesis of oligosaccharides, which finally evolve the OPG or advance parallelly, are briefly described at the beginning. .COPYRGT. 2005 Bentham Science Publishers Ltd.

L15 ANSWER 6 OF 6 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004229185 EMBASE

TITLE: Fluorous thiols in oligosaccharide synthesis.

AUTHOR: Jing Y.; Huang X.

CORPORATE SOURCE: X. Huang, Department of Chemistry, University of Toledo, 2801 W. Bancroft Street, Toledo, OH 43606-3390, United States. xuefei.huang@utoledo.edu

SOURCE: Tetrahedron Letters, (7 Jun 2004) Vol. 45, No. 24, pp. 4615-4618. .

Refs: 38

ISSN: 0040-4039 CODEN: TELEAY

PUBLISHER IDENT.: S 0040-4039(04)00920-7

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 029 Clinical Biochemistry  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 20040628  
Last Updated on STN: 20040628

AB A new, almost odorless fluorous thiol is synthesized, which is utilized to prepare highly fluorinated thioglycosyl donors. These thioglycosides showed excellent reactivities in glycosylation **reactions**. The fluorous chain, stable under esterification, etherification, deacetylation, and **glycosylation** conditions, allowed facile **purification** of the thioglycosides by solid-phase extraction through fluorous silica gel. The fluorous thiol was readily recycled.  
.COPYRGT. 2004 Elsevier Ltd. All rights reserved.

=> logoff h  
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
--	---------------------	------------------

FULL ESTIMATED COST

133.90	134.11
--------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

	SINCE FILE ENTRY	TOTAL SESSION
--	---------------------	------------------

CA SUBSCRIBER PRICE

-18.00	-18.00
--------	--------

SESSION WILL BE HELD FOR 60 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 13:42:59 ON 21 MAR 2006

=> d que stat 137

L33 289 SEA FILE=HCAPLUS ABB=ON ?GLYCOSYLAT?(W)?PROTEIN? AND (?SEPARAT  
? OR GEL?(W)?ELECTROPHORES?)  
L34 1 SEA FILE=HCAPLUS ABB=ON L33 AND ?RESIN?(3A)?NUCLEOPHIL?  
L35 2 SEA FILE=HCAPLUS ABB=ON L33 AND ?RESIN?  
L36 2 SEA FILE=HCAPLUS ABB=ON L34 OR L35  
L37 1 SEA FILE=HCAPLUS ABB=ON L36 AND (PRD<20031031 OR PD<20031031)

=> d ibib abs 137 1-1

L37 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1983:419076 HCAPLUS  
DOCUMENT NUMBER: 99:19076  
TITLE: Characterization of glycosylated hemoglobins.  
Relevance to monitoring of diabetic control and  
analysis of other proteins  
AUTHOR(S): Garlick, Robert L.; Mazer, Jonathan S.; Higgins, Paul  
J.; Bunn, H. Franklin  
CORPORATE SOURCE: Howard Hughes Med. Inst., Harvard Med. Sch., Boston,  
MA, 02115, USA  
SOURCE: Journal of Clinical Investigation (1983),  
71(5), 1062-72  
CODEN: JCINAO; ISSN: 0021-9738  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Boronate affinity chromatog. and ion-exchange chromatog. were used to measure the levels of glycosylated Hbs in normal and diabetic hemolyzates, as well as the distribution of glucose adducts on  $\alpha$ -NH<sub>2</sub>-valine and  $\epsilon$ -NH<sub>2</sub>-lysine residues. When analyzed by ion-exchange chromatog. on BioRex 70 resin, the Hb A1c peak comprised 4.4% of 15 normal hemolyzates and 9.1% of 15 diabetic hemolyzates. The Hb A1c was rechromatographed on GlycoGel B boronate affinity resin that binds vicinal hydroxyl groups of covalently linked sugars. Only 70% of the Hb adhered to the resin. Anal. by the thiobarbituric acid colorimetric test confirmed that the affinity resin effectively separated glycosylated from nonglycosylated Hb. When corrected for nonglycosylated contaminants, the mean level of Hb A1c in normal hemolyzates was 2.9%, a value considerably lower than those previously reported. In addition to Hb A1c, 5.2% of the remaining Hb (Hb A0) was glycosylated. In diabetics, glycosylated A0 was increased in parallel with Hb A1c. After reduction with [3H]borohydride and acid hydrolysis, glycosylated amino acids were 1st purified on Affi-Gel boronate affinity resin and then analyzed by ion-exchange chromatog. The glucose adducts on Hb A0 were distributed as follows:  $\alpha$ -chain N-terminal valine, 14%;  $\alpha$ -chain lysines, 40%;  $\beta$ -chain lysines, 46%. Several pitfalls in the anal. of nonenzymically glycosylated proteins were revealed. Peaks isolated by ion-exchange chromatog. or electrophoresis are likely to be contaminated by nonglycosylated proteins. Furthermore, both the thiobarbituric acid test and [3H]borohydride reduction show variable reactivity depending upon the site of the ketoamine-linked glucose.

=> => d que stat 139

L33 289 SEA FILE=HCAPLUS ABB=ON ?GLYCOSYLAT?(W)?PROTEIN? AND (?SEPARAT  
? OR GEL?(W)?ELECTROPHORES?)  
L34 1 SEA FILE=HCAPLUS ABB=ON L33 AND ?RESIN?(3A)?NUCLEOPHIL?  
L35 2 SEA FILE=HCAPLUS ABB=ON L33 AND ?RESIN?

L36 2 SEA FILE=HCAPLUS ABB=ON L34 OR L35  
 L38 4 SEA L36  
 L39 2 DUP REMOV L38 (2 DUPLICATES REMOVED)

=> d ibib abs 139 1-2

L39 ANSWER 1 OF 2 MEDLINE on STN  
 ACCESSION NUMBER: 1998242562 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 9581461  
 TITLE: The effects of reductive dissociation of gastric mucin isolated in the presence of proteinase inhibitors.  
 AUTHOR: Minkiewicz I; Gindzienski A; Kisiel D G  
 CORPORATE SOURCE: Departament of General and Organic Chemistry, Medical Academy of Bialystok.  
 SOURCE: Roczniki Akademii Medycznej w Bialymstoku (1995), (1997) 42 (1) 26-34.  
 Journal code: 9515551.  
 PUB. COUNTRY: Poland  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 199806  
 ENTRY DATE: Entered STN: 19980618  
 Last Updated on STN: 19980618  
 Entered Medline: 19980609

AB Mucin was purified by the gel filtration method on columns with high porous molecular sives in buffers with SDS and proteinase inhibitors. The addition of proteinase inhibitors distinctly inhibited proteolytic activity. It was found that the obtained mucin, after disulphide-bound reduction, is dissociated to mucin subunits and **N-glycosylated glycoprotein** of molecular weight about 75 kDa. This protein has carbohydrate and amino acid composition different from high molecular fraction. The 75 kDa protein is strongly associated with high molecular mass mucin subunits and can be **separated** either during electrophoresis or fractionation in buffers with 2-mercaptoethanol.

L39 ANSWER 2 OF 2 MEDLINE on STN DUPLICATE 1  
 ACCESSION NUMBER: 83213912 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 6406542  
 TITLE: Characterization of glycosylated hemoglobins. Relevance to monitoring of diabetic control and analysis of other proteins.  
 AUTHOR: Garlick R L; Mazer J S; Higgins P J; Bunn H F  
 CONTRACT NUMBER: AM-18223 (NIADDK)  
 SOURCE: Journal of clinical investigation, (1983 May) 71 (5) 1062-72.  
 Journal code: 7802877. ISSN: 0021-9738.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
 ENTRY MONTH: 198307  
 ENTRY DATE: Entered STN: 19900319  
 Last Updated on STN: 19970203  
 Entered Medline: 19830708

AB Boronate affinity chromatography and ion exchange chromatography were used to measure the levels of glycosylated hemoglobins in normal and diabetic hemolysates, as well as the distribution of glucose adducts on alpha-NH2-valine and epsilon-NH2-lysine residues. When analyzed by ion

exchange chromatography on BioRex 70 **resin**, the Hb Alc peak comprised 4.4 +/- 0.6% of 15 normal hemolysates and 9.1 +/- 2.1% of 15 diabetic hemolysates. The "Hb Alc" was rechromatographed on GlycoGel B boronate affinity **resin** that binds vicinal hydroxyl groups of covalently linked sugars. Only 70 +/- 5% of the hemoglobin adhered to the **resin**. Analysis by the thiobarbituric acid colorimetric test confirmed that the affinity **resin** effectively **separated** glycosylated from nonglycosylated hemoglobin. When corrected for nonglycosylated contaminants, the mean level of Hb Alc in normal hemolysates was 2.9 +/- 0.4%, a value considerably lower than those previously reported. In addition to Hb Alc, 5.2 +/- 0.5% of the remaining hemoglobin (Hb Ao) was glycosylated. In diabetics, glycosylated Ao was increased in parallel with Hb Alc. After reduction with [3H]borohydride and acid hydrolysis, glycosylated amino acids were first purified on Affi-Gel boronate affinity **resin** and then analyzed by ion exchange chromatography. The glucose adducts on Hb Ao were distributed as follows: alpha-chain N-terminal valine, 14%; alpha-chain lysines, 40%; beta-chain lysines, 46%. This study has revealed several pitfalls in the analysis of nonenzymatically **glycosylated proteins**. Peaks isolated by ion exchange chromatography or electrophoresis are likely to be contaminated by **nonglycosylated proteins**. Furthermore, both the thiobarbituric acid test and [3H]borohydride reduction show variable reactivity depending upon the site of the ketoamine-linked glucose.

=>

```
=> d que stat 147
L33      289 SEA FILE=HCAPLUS ABB=ON ?GLYCOSYLAT?(W)?PROTEIN? AND (?SEPARAT
          ? OR GEL?(W)?ELECTROPHORES?)
L34      1 SEA FILE=HCAPLUS ABB=ON L33 AND ?RESIN?(3A)?NUCLEOPHIL?
L35      2 SEA FILE=HCAPLUS ABB=ON L33 AND ?RESIN?
L36      2 SEA FILE=HCAPLUS ABB=ON L34 OR L35
L40      1440 SEA FILE=USPATFULL ABB=ON L36 AND (PRD<20031031 OR PD<20031031
          )
L41      1058 SEA FILE=USPATFULL ABB=ON L40 AND GEL?(W)?ELECTROPHOR?
L42      1023 SEA FILE=USPATFULL ABB=ON L41 AND ?CHROMATOG?
L43      650 SEA FILE=USPATFULL ABB=ON L42 AND (HPLC OR ?HIGH?(W)?PRESS?(W)
          ?LIQUID?(W)?CHROMATOG?)
L44      56 SEA FILE=USPATFULL ABB=ON L43 AND ?NUCLEOPHIL?
L46      49 SEA FILE=USPATFULL ABB=ON L44 AND KIT?
L47      25 SEA FILE=USPATFULL ABB=ON L46 AND (?SOLID?(W)?PHASE?(W)?SYNTH?
          )
```

=> d ibib abs 147 1-25

L47 ANSWER 1 OF 25 USPATFULL on STN  
 ACCESSION NUMBER: 2006:34747 USPATFULL  
 TITLE: Remodeling and glycoconjugation of peptides  
 INVENTOR(S): DeFrees, Shawn, North Wales, PA, UNITED STATES  
 Zopf, David, Wayne, PA, UNITED STATES  
 Bayer, Robert, San Diego, CA, UNITED STATES  
 Bowe, Caryn, Doylestown, PA, UNITED STATES  
 Hakes, David, Willow Grove, PA, UNITED STATES  
 Chen, Xi, Lansdale, PA, UNITED STATES  
 PATENT ASSIGNEE(S): Neose Technologies, Inc., Horsham, PA, UNITED STATES  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006030521	A1	20060209
APPLICATION INFO.:	US 2005-183205	A1	20050715 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-287994, filed on 5 Nov 2002, PENDING Continuation of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING		

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-407527P	20020828 (60)	<--
	US 2002-404249P	20020816 (60)	<--
	US 2002-396594P	20020717 (60)	<--
	US 2002-391777P	20020625 (60)	<--
	US 2002-387292P	20020607 (60)	<--
	US 2001-334301P	20011128 (60)	<--
	US 2001-334233P	20011128 (60)	<--

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP (SF), 2 PALO ALTO SQUARE, 3000 El Camino Real, Suite 700, PALO ALTO, CA, 94306, US  
 NUMBER OF CLAIMS: 43  
 EXEMPLARY CLAIM: 1-57  
 NUMBER OF DRAWINGS: 345 Drawing Page(s)

LINE COUNT: 16410

AB .The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

L47 ANSWER 2 OF 25 USPATFULL on STN

ACCESSION NUMBER: 2005:144275 USPATFULL

TITLE: Whole cell engineering by mutagenizing a substantial portion of a starting genome combining mutations and optionally repeating

INVENTOR(S): Short, Jay M, Rancho Santa Fe, CA, UNITED STATES  
 Fu, Pengcheng, Lowrey Avenue, HI, UNITED STATES  
 Wei, Jing, San Diego, CA, UNITED STATES  
 Levin, Michael, San Diego, CA, UNITED STATES  
 Latterich, Martin, Montellano Terrace, San Diego, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 2005124010	A1	20050609
APPLICATION INFO.:	US 2003-398271	A1	20011001 (10)
	WO 2001-US31004		20011001

NUMBER	DATE
--------	------

PRIORITY INFORMATION:	US 2003-9677584	20000930	<--
	US 2003-279702P	20010328 (60)	<--

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FISH &amp; RICHARDSON, PC, 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130-2081, US

NUMBER OF CLAIMS: 179

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 31 Drawing Page(s)

LINE COUNT: 31291

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the field of cellular and whole organism engineering. Specifically, this invention relates to a cellular transformation, directed evolution, and screening method for creating novel transgenic organisms having desirable properties. Thus in one aspect, this invention relates to a method of generating a transgenic organism, such as a microbe or a plant, having a plurality of traits that are differentially activatable.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 3 OF 25 USPATFULL on STN

ACCESSION NUMBER: 2005:124269 USPATFULL

TITLE: Remodeling and glycoconjugation of peptides

INVENTOR(S): DeFrees, Shawn, North Wales, PA, UNITED STATES  
 Zopf, David, Wayne, PA, UNITED STATES  
 Bayer, Robert, San Diego, CA, UNITED STATES  
 Bowe, Caryn, Doylestown, PA, UNITED STATES  
 Hakes, David, Willow Grove, PA, UNITED STATES  
 Chen, Xi, Woodland, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 2005106658	A1	20050519
---------------------	---------------	----	----------

APPLICATION INFO.: US 2003-492261 A1 20021009 (10)  
 WO 2002-US32263 20021009

PRIORITY INFORMATION:	NUMBER	DATE	---
	US 2003-328523P	20011010 (60)	<--
	US 2003-344692P	20011019 (60)	<--
	US 2003-334233P	20011128 (60)	<--
	US 2003-334301P	20011128 (60)	<--
	US 2003-387292P	20020607 (60)	<--
	US 2003-391777P	20020625 (60)	<--
	US 2003-396594P	20020717 (60)	<--
	US 2003-404249P	20020816 (60)	<--
	US 2003-407527P	20020828 (60)	<--

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921, US

NUMBER OF CLAIMS: 447

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 345 Drawing Page(s)

LINE COUNT: 18300

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group of peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 4 OF 25 USPATFULL on STN

ACCESSION NUMBER: 2005:117715 USPATFULL

TITLE: Factor IX: remodeling and glycoconjugation of factor IX

INVENTOR(S): Defrees, Shawn, North Wales, PA, UNITED STATES

Zopf, David, Wayne, PA, UNITED STATES

Bayer, Robert, San Diego, CA, UNITED STATES

Bowe, Caryn, Doylestown, PA, UNITED STATES

Hakes, David, Willow Grove, PA, UNITED STATES

Chen, Xi, Lansdale, PA, UNITED STATES

PATENT ASSIGNEE(S): Neose Technologies, Inc. (U.S. corporation)

PATENT INFORMATION:	NUMBER	KIND	DATE
---------------------	--------	------	------

APPLICATION INFO.: US 2005100982 A1 20050512

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003, PENDING Continuation-in-part of Ser. No. US 2003-360770, filed on 6 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2002-287994, filed on 5 Nov 2002, PENDING Continuation of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING

PRIORITY INFORMATION:	NUMBER	DATE
-----------------------	--------	------

	US 2002-407527P	20020828 (60)	<--
	US 2002-404249P	20020816 (60)	<--
	US 2002-396594P	20020717 (60)	<--
	US 2002-391777P	20020625 (60)	<--
	US 2002-387292P	20020607 (60)	<--
	US 2001-334301P	20011128 (60)	<--

DOCUMENT TYPE: US 2001-334233P 20011128 (60) <--  
 FILE SEGMENT: Utility  
 APPLICATION  
 LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,  
 PHILADELPHIA, PA, 19103-2921, US  
 NUMBER OF CLAIMS: 88  
 EXEMPLARY CLAIM: 1-112  
 NUMBER OF DRAWINGS: 497 Drawing Page(s)  
 LINE COUNT: 19035  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 5 OF 25 USPATFULL on STN  
 ACCESSION NUMBER: 2005:36910 USPATFULL  
 TITLE: Interleukin-2:remodeling and glycoconjugation of interleukin-2  
 INVENTOR(S): DeFrees, Shawn, North Wales, PA, UNITED STATES  
 Zopf, David, Wayne, PA, UNITED STATES  
 Bayer, Robert, San Diego, CA, UNITED STATES  
 Bowe, Caryn, Doylestown, PA, UNITED STATES  
 Hakes, David, Willow Grove, PA, UNITED STATES  
 Chen, Xi, Lansdale, PA, UNITED STATES  
 PATENT ASSIGNEE(S): Neose Technologies, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005031584	A1	20050210	
APPLICATION INFO.:	US 2003-410980	A1	20030409 (10)	
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003, PENDING Continuation-in-part of Ser. No. US 2003-360770, filed on 6 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2002-287994, filed on 5 Nov 2002, PENDING Continuation of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING			

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-407527P	20020828 (60)	<--
	US 2002-404249P	20020816 (60)	<--
	US 2002-396594P	20020717 (60)	<--
	US 2002-391777P	20020625 (60)	<--
	US 2002-387292P	20020607 (60)	<--
	US 2001-334301P	20011128 (60)	<--
	US 2001-334233P	20011128 (60)	<--
	US 2001-344692P	20011019 (60)	<--
	US 2001-328523P	20011010 (60)	<--

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,  
 PHILADELPHIA, PA, 19103-2921  
 NUMBER OF CLAIMS: 111  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 497 Drawing Page(s)  
 LINE COUNT: 19059  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 6 OF 25 USPATFULL on STN

ACCESSION NUMBER: 2004:184970 USPATFULL

TITLE: Glycoconjugation methods and proteins/peptides produced by the methods

INVENTOR(S): DeFrees, Shawn, North Wales, PA, UNITED STATES

Zopf, David, Wayne, PA, UNITED STATES

Bayer, Robert, San Diego, CA, UNITED STATES

Bowe, Caryn, Doylestown, PA, UNITED STATES

Hakes, David, Willow Grove, PA, UNITED STATES

Chen, Xi, Lansdale, PA, UNITED STATES

PATENT ASSIGNEE(S): Neose Technologies, Inc. (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

-----	-----	-----
-------	-------	-------

PATENT INFORMATION:

US 2004142856 A1 20040722

APPLICATION INFO.:

US 2003-410913 A1 20030409 (10)

RELATED APPLN. INFO.:

Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003, PENDING Continuation-in-part of Ser. No. US 2003-360770, filed on 6 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2002-287994, filed on 5 Nov 2002, PENDING Continuation of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING

NUMBER	DATE
--------	------

-----	-----
-------	-------

PRIORITY INFORMATION:

US 2002-407527P 20020828 (60) <--

US 2002-407527P 20020828 (60) <--

US 2002-404249P 20020816 (60) <--

US 2002-396594P 20020717 (60) <--

US 2002-391777P 20020625 (60) <--

US 2002-387292P 20020607 (60) <--

US 2001-334301P 20011128 (60) <--

US 2001-334233P 20011128 (60) <--

US 2001-334692P 20011121 (60) <--

US 2001-328523P 20011010 (60) <--

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921

NUMBER OF CLAIMS: 88

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 497 Drawing Page(s)

LINE COUNT: 16544

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 7 OF 25 USPATFULL on STN

ACCESSION NUMBER: 2004:178391 USPATFULL

TITLE: Remodeling and glycoconjugation of peptides  
 INVENTOR(S): DeFrees, Shawn, North Wales, PA, UNITED STATES  
 Zopf, David, Wayne, PA, UNITED STATES  
 Bayer, Robert, San Diego, CA, UNITED STATES  
 Bowe, Caryn, Doylestown, PA, UNITED STATES  
 Hakes, David, Willow Grove, PA, UNITED STATES  
 Chen, Xi, Lansdale, PA, UNITED STATES  
 PATENT ASSIGNEE(S): Neose Technologies, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004137557	A1	20040715
APPLICATION INFO.:	US 2002-287994	A1	20021105 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING		

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-407527P	20020828 (60)	<--
	US 2002-404249P	20020816 (60)	<--
	US 2002-396594P	20020717 (60)	<--
	US 2002-391777P	20020625 (60)	<--
	US 2002-387292P	20020607 (60)	<--
	US 2001-334301P	20011128 (60)	<--
	US 2001-334233P	20011128 (60)	<--

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,  
 PHILADELPHIA, PA, 19103-2921  
 NUMBER OF CLAIMS: 447  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 345 Drawing Page(s)  
 LINE COUNT: 16205  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group a peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 8 OF 25 USPATFULL on STN  
 ACCESSION NUMBER: 2004:173771 USPATFULL  
 TITLE: Enzyme  
 INVENTOR(S): Rossiter, John, Kent, UNITED KINGDOM  
 Bones, Atle, Trondheim, NORWAY  
 Jones, Alex, Kent, UNITED KINGDOM  
 Winge, Per, Trondheim, NORWAY

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004133936	A1	20040708
APPLICATION INFO.:	US 2003-362024	A1	20030925 (10)
	WO 2001-GB3670		20010816

	NUMBER	DATE	
PRIORITY INFORMATION:	GB 2000-20331	20000817	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	NIXON & VANDERHYE, PC, 1100 N GLEBE ROAD, 8TH FLOOR,		

ARLINGTON, VA, 22201-4714

NUMBER OF CLAIMS: 22  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 7 Drawing Page(s)  
 LINE COUNT: 2490

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Amino acid sequences and nucleotide sequences relating to aphid myrosinase are described. In a preferred aspect, the amino acid sequence comprises the sequence presented as SEQ ID Number 1.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 9 OF 25 USPATFULL on STN

ACCESSION NUMBER: 2004:172476 USPATFULL  
 TITLE: Glycopeylation methods and proteins/peptides produced by the methods  
 INVENTOR(S): DeFrees, Shawn, North Wales, PA, UNITED STATES  
 Zopf, David, Wayne, PA, UNITED STATES  
 Bayer, Robert, San Diego, CA, UNITED STATES  
 Bowe, Caryn, Doylestown, PA, UNITED STATES  
 Hakes, David, Willow Grove, PA, UNITED STATES  
 Chen, Xi, Lansdale, PA, UNITED STATES  
 PATENT ASSIGNEE(S): Neose Technologies, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004132640	A1	20040708
APPLICATION INFO.:	US 2003-411012	A1	20030409 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING		

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-407527P	20020828 (60)	<--
	US 2002-404249P	20020816 (60)	<--
	US 2002-396594P	20020717 (60)	<--
	US 2002-391777P	20020625 (60)	<--
	US 2002-387292P	20020607 (60)	<--

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921

NUMBER OF CLAIMS: 77  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 497 Drawing Page(s)  
 LINE COUNT: 19255

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 10 OF 25 USPATFULL on STN

ACCESSION NUMBER: 2004:165351 USPATFULL  
 TITLE: Follicle stimulating hormone: remodeling and glycoconjugation of FSH  
 INVENTOR(S): DeFrees, Shawn, North Wales, PA, UNITED STATES  
 Zopf, David, Wayne, PA, UNITED STATES

Bayer, Robert, San Diego, CA, UNITED STATES  
 Bowe, Caryn, Doylestown, PA, UNITED STATES  
 Hakes, David, Willow Grove, PA, UNITED STATES  
 Chen, Xi, Lansdale, PA, UNITED STATES  
 Neose Technologies, Inc. (U.S. corporation)

## PATENT ASSIGNEE(S):

NUMBER	KIND	DATE
--------	------	------

## PATENT INFORMATION:

US 2004126838	A1	20040701
---------------	----	----------

## APPLICATION INFO.:

US 2003-410997	A1	20030409 (10)
----------------	----	---------------

## RELATED APPLN. INFO.:

Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003, PENDING
--

Continuation-in-part of Ser. No. US 2003-360770, filed on 6 Jan 2003, PENDING

Continuation-in-part of Ser. No. US 2002-287994, filed on 5 Nov 2002, PENDING

Continuation of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING

NUMBER	DATE
--------	------

## PRIORITY INFORMATION:

US 2002-407527P	20020828 (60)	<--
US 2002-404249P	20020816 (60)	<--
US 2002-396594P	20020717 (60)	<--
US 2002-391777P	20020625 (60)	<--
US 2002-387292P	20020607 (60)	<--
US 2001-334301P	20011128 (60)	<--
US 2001-334233P	20011128 (60)	<--

## DOCUMENT TYPE:

Utility

## FILE SEGMENT:

APPLICATION

## LEGAL REPRESENTATIVE:

MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,  
PHILADELPHIA, PA, 19103-2921

## NUMBER OF CLAIMS:

115

## EXEMPLARY CLAIM:

1

## NUMBER OF DRAWINGS:

497 Drawing Page(s)

## LINE COUNT:

19355

## CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

## CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 11 OF 25 USPATFULL on STN

ACCESSION NUMBER: 2004:150947 USPATFULL

TITLE: Interferon beta: remodeling and glycoconjugation of interferon beta

INVENTOR(S): DeFrees, Shawn, North Wales, PA, UNITED STATES

Zopf, David, Wayne, PA, UNITED STATES

Bayer, Robert, San Diego, CA, UNITED STATES

Bowe, Caryn, Doylestown, PA, UNITED STATES

Hakes, David, Willow Grove, PA, UNITED STATES

Chen, Xi, Lansdale, PA, UNITED STATES

PATENT ASSIGNEE(S): Neose Technologies, Inc. (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

## PATENT INFORMATION:

US 2004115168	A1	20040617
---------------	----	----------

## APPLICATION INFO.:

US 2003-410930	A1	20030409 (10)
----------------	----	---------------

## RELATED APPLN. INFO.:

Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003, PENDING
--

No. US 2003-360770, filed on 6 Jan 2003, PENDING  
 Continuation-in-part of Ser. No. US 2002-287994, filed  
 on 5 Nov 2002, PENDING Continuation of Ser. No. WO  
 2002-US32263, filed on 9 Oct 2002, PENDING

PRIORITY INFORMATION:	NUMBER	DATE	---
	US 2002-407527P	20020828 (60)	<--
	US 2002-404249P	20020816 (60)	<--
	US 2002-396594P	20020717 (60)	<--
	US 2002-391777P	20020625 (60)	<--
	US 2002-387292P	20020607 (60)	<--
	US 2001-334301P	20011128 (60)	<--
	US 2001-334233P	20011128 (60)	<--
	US 2001-344692P	20011019 (60)	<--
	US 2001-328523P	20011010 (60)	<--

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,  
 PHILADELPHIA, PA, 19103-2921

NUMBER OF CLAIMS: 119

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 497 Drawing Page(s)

LINE COUNT: 19412

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 12 OF 25 USPATFULL on STN

ACCESSION NUMBER: 2004:107626 USPATFULL

TITLE: Interferon alpha: remodeling and glycoconjugation of interferon alpha

INVENTOR(S): DeFrees, Shawn, North Wales, PA, UNITED STATES

Zopf, David, Wayne, PA, UNITED STATES

Bayer, Robert, San Diego, CA, UNITED STATES

Bowe, Caryn, Doylestown, PA, UNITED STATES

Hakes, David, Willow Grove, PA, UNITED STATES

Chen, Xi, Lansdale, PA, UNITED STATES

PATENT ASSIGNEE(S): Neose Technologies, Inc. (U.S. corporation)

PATENT INFORMATION:	NUMBER	KIND	DATE
	US 2004082026	A1	20040429
APPLICATION INFO.:	US 2003-411049	A1	20030409 (10)
RELATED APPLN. INFO.:			Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003, PENDING Continuation-in-part of Ser. No. US 2003-360770, filed on 6 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2002-287994, filed on 5 Nov 2002, PENDING Continuation of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING

PRIORITY INFORMATION:	NUMBER	DATE	---
	US 2002-407527P	20020828 (60)	<--
	US 2002-404249P	20020816 (60)	<--
	US 2002-396594P	20020717 (60)	<--

US 2002-391777P	20020625 (60)	<--
US 2002-387292P	20020607 (60)	<--
US 2001-334301P	20011128 (60)	<--
US 2001-334233P	20011128 (60)	<--
US 2001-344692P	20011019 (60)	<--
US 2001-328523P	20011010 (60)	<--

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,  
PHILADELPHIA, PA, 19103-2921

NUMBER OF CLAIMS: 126

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 497 Drawing Page(s)

LINE COUNT: 19445

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention includes a multitude of methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 13 OF 25 USPATFULL on STN

ACCESSION NUMBER: 2004:101966 USPATFULL

TITLE: Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF

INVENTOR(S): DeFrees, Shawn, North Wales, PA, UNITED STATES

Zopf, David, Wayne, PA, UNITED STATES

Bayer, Robert, San Diego, CA, UNITED STATES

Bowe, Caryn, Doylestown, PA, UNITED STATES

Hakes, David, Willow Grove, PA, UNITED STATES

Chen, Xi, Lansdale, PA, UNITED STATES

PATENT ASSIGNEE(S): Neose Technologies, Inc. (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

US 2004077836	A1	20040422
---------------	----	----------

US 2003-410962	A1	20030409 (10)
----------------	----	---------------

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003, PENDING Continuation-in-part of Ser. No. US 2003-360770, filed on 6 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2002-287994, filed on 5 Nov 2002, PENDING Continuation of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING

NUMBER	DATE
--------	------

US 2002-407527P	20020828 (60)	<--
-----------------	---------------	-----

US 2002-404249P	20020816 (60)	<--
-----------------	---------------	-----

US 2002-396594P	20020717 (60)	<--
-----------------	---------------	-----

US 2002-391777P	20020625 (60)	<--
-----------------	---------------	-----

US 2002-387292P	20020607 (60)	<--
-----------------	---------------	-----

US 2001-334301P	20011128 (60)	<--
-----------------	---------------	-----

US 2001-334233P	20011128 (60)	<--
-----------------	---------------	-----

US 2001-344692P	20011019 (60)	<--
-----------------	---------------	-----

US 2001-328523P	20011010 (60)	<--
-----------------	---------------	-----

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,  
PHILADELPHIA, PA, 19103-2921

NUMBER OF CLAIMS: 111  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 497 Drawing Page(s)  
 LINE COUNT: 19316

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 14 OF 25 USPATFULL on STN  
 ACCESSION NUMBER: 2004:101228 USPATFULL  
 TITLE: Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating  
 INVENTOR(S): Short, Jay M., Rancho Santa Fe, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004077090	A1	20040422
APPLICATION INFO.:	US 2003-383798	A1	20030306 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-677584, filed on 30 Sep 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-594459, filed on 14 Jun 2000, GRANTED, Pat. No. US 6605449 Continuation-in-part of Ser. No. US 2000-522289, filed on 9 Mar 2000, GRANTED, Pat. No. US 6358709 Continuation-in-part of Ser. No. US 2000-498557, filed on 4 Feb 2000, PENDING Continuation-in-part of Ser. No. US 2000-495052, filed on 31 Jan 2000, GRANTED, Pat. No. US 6479258		

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1999-156815P	19990929 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HALE AND DORR LLP, 300 PARK AVENUE, NEW YORK, NY, 10022		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	28 Drawing Page(s)		
LINE COUNT:	37121		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An invention comprising cellular transformation, directed evolution, and screening methods for creating novel transgenic organisms having desirable properties. Thus in one aspect, this invention relates to a method of generating a transgenic organism, such as a microbe or a plant, having a plurality of traits that are differentially activatable. Also, a method of retooling genes and gene pathways by the introduction of regulatory sequences, such as promoters, that are operable in an intended host, thus conferring operability to a novel gene pathway when it is introduced into an intended host. For example a novel man-made gene pathway, generated based on microbially-derived progenitor templates, that is operable in a plant cell. Furthermore, a method of generating novel host organisms having increased expression of desirable traits, recombinant genes, and gene products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 15 OF 25 USPATFULL on STN  
 ACCESSION NUMBER: 2004:83455 USPATFULL  
 TITLE: Protein remodeling methods and proteins/peptides produced by the methods  
 INVENTOR(S): DeFrees, Shawn, North Wales, PA, UNITED STATES  
 Zopf, David, Wayne, PA, UNITED STATES  
 Bayer, Robert, San Diego, CA, UNITED STATES  
 Hakes, David, Willow Grove, PA, UNITED STATES  
 Chen, Xi, Lansdale, PA, UNITED STATES  
 PATENT ASSIGNEE(S): Neose Technologies, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004063911	A1	20040401
APPLICATION INFO.:	US 2003-411026	A1	20030409 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003, PENDING Continuation-in-part of Ser. No. US 2003-360770, filed on 6 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2002-287994, filed on 5 Nov 2002, PENDING Continuation of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING		

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-407527P	20020828 (60)	<--
	US 2002-404249P	20020816 (60)	<--
	US 2002-396594P	20020717 (60)	<--
	US 2002-391777P	20020625 (60)	<--
	US 2002-387292P	20020607 (60)	<--
	US 2001-334301P	20011128 (60)	<--
	US 2001-334233P	20011128 (60)	<--
	US 2001-344692P	20011019 (60)	<--
	US 2001-328523P	20011010 (60)	<--

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921  
 NUMBER OF CLAIMS: 39  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 497 Drawing Page(s)  
 LINE COUNT: 18872  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 16 OF 25 USPATFULL on STN  
 ACCESSION NUMBER: 2004:57444 USPATFULL  
 TITLE: Alpha galactosidase a: remodeling and glycoconjugation of alpha galactosidase A  
 INVENTOR(S): DeFrees, Shawn, North Wales, PA, UNITED STATES  
 Zopf, David, Wayne, PA, UNITED STATES  
 Bayer, Robert, San Diego, CA, UNITED STATES  
 Bowe, Caryn, Doylestown, PA, UNITED STATES  
 Hakes, David, Willow Grove, PA, UNITED STATES  
 Chen, Xi, Lansdale, PA, UNITED STATES  
 PATENT ASSIGNEE(S): Neose Technologies, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004043446	A1	20040304
APPLICATION INFO.:	US 2003-411037	A1	20030409 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING		

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-407527P	20020828 (60)	<--
	US 2002-404249P	20020816 (60)	<--
	US 2002-396594P	20020717 (60)	<--
	US 2002-391777P	20020625 (60)	<--
	US 2002-387292P	20020607 (60)	<--

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,  
PHILADELPHIA, PA, 19103-2921

NUMBER OF CLAIMS:

122

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

497 Drawing Page(s)

LINE COUNT:

19395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 17 OF 25 USPATFULL on STN

ACCESSION NUMBER: 2003:243837 USPATFULL

TITLE: Lipophilin complexes for use in cancer diagnosis and therapy

INVENTOR(S): Fanger, Gary R., Mill Creek, WA, UNITED STATES  
 Durham, Margarita, Seattle, WA, UNITED STATES  
 Houghton, Raymond L., Bothell, WA, UNITED STATES  
 Dillon, Davin C., Issaquah, WA, UNITED STATES  
 Carter, Darrick, Seattle, WA, UNITED STATES  
 Persing, David H., Redmond, WA, UNITED STATES

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003170246	A1	20030911	<--
APPLICATION INFO.:	US 2002-96319	A1	20020312 (10)	
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-905673, filed on 13 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2001-780842, filed on 8 Feb 2001, ABANDONED			

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-215735P	20000628 (60)	<--
	US 2000-183495P	20000211 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092		

NUMBER OF CLAIMS: 57  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 16 Drawing Page(s)  
 LINE COUNT: 3906

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of breast, ovarian and prostate cancer are disclosed. Compositions may comprise one or more lipophilin fusion proteins, which comprise at least two different lipophilin-like polypeptides linked by a peptide bond. Such compositions may be used for the prevention and treatment of breast, ovarian and prostate cancer. Diagnostic methods based on detecting the presence of lipophilin complexes, or antibodies thereto, in a patient are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 18 OF 25 USPATFULL on STN  
 ACCESSION NUMBER: 2003:237907 USPATFULL  
 TITLE: Compositions and methods for the therapy and diagnosis of colon cancer  
 INVENTOR(S): King, Gordon E., Shoreline, WA, UNITED STATES  
 Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
 Xu, Jiangchun, Bellevue, WA, UNITED STATES  
 Secrist, Heather, Seattle, WA, UNITED STATES  
 Jiang, Yuqiu, Kent, WA, UNITED STATES  
 PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104  
 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003166064	A1	20030904	<--
APPLICATION INFO.:	US 2002-99926	A1	20020314 (10)	
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-33528, filed on 26 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001, PENDING			

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-302051P	20010629 (60)	<--
	US 2001-279763P	20010328 (60)	<--
	US 2000-223283P	20000803 (60)	<--

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 17  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 8531

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 19 OF 25 USPATFULL on STN  
 ACCESSION NUMBER: 2003:228246 USPATFULL  
 TITLE: Methods of determining SAM-dependent methyltransferase activity using a mutant SAH hydrolase  
 INVENTOR(S): Yuan, Chong-Sheng, San Diego, CA, United States  
 PATENT ASSIGNEE(S): General Atomics, San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6610504	B1	20030826	<--
APPLICATION INFO.:	US 2000-546013		20000410 (9)	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Prouty, Rebecca E.			
ASSISTANT EXAMINER:	Steadman, David J.			
LEGAL REPRESENTATIVE:	Morrison & Foerster LLP			
NUMBER OF CLAIMS:	17			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)			
LINE COUNT:	6392			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions and methods for assaying the activity of methyltransferases, such as S-adenosylmethionine (SAM)-dependent methyltransferases. The methods can be used for screening for modulators of such methyltransferases, for identifying substrates and for diagnostics. The methods are amenable for use in high throughput formats. Kits for performing the methods are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 20 OF 25 USPATFULL on STN  
 ACCESSION NUMBER: 2003:106233 USPATFULL  
 TITLE: Compositions and methods for the therapy and diagnosis of pancreatic cancer  
 INVENTOR(S): Benson, Darin R., Seattle, WA, UNITED STATES  
 Kalos, Michael D., Seattle, WA, UNITED STATES  
 Lodes, Michael J., Seattle, WA, UNITED STATES  
 Persing, David H., Redmond, WA, UNITED STATES  
 Hepler, William T., Seattle, WA, UNITED STATES  
 Jiang, Yuqiu, Kent, WA, UNITED STATES  
 PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003073144	A1	20030417	<--
APPLICATION INFO.:	US 2002-60036	A1	20020130 (10)	

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-333626P	20011127 (60)	<--
	US 2001-305484P	20010712 (60)	<--
	US 2001-265305P	20010130 (60)	<--
	US 2001-267568P	20010209 (60)	<--
	US 2001-313999P	20010820 (60)	<--
	US 2001-291631P	20010516 (60)	<--
	US 2001-287112P	20010428 (60)	<--
	US 2001-278651P	20010321 (60)	<--

DOCUMENT TYPE: US 2001-265682P 20010131 (60) <--  
 FILE SEGMENT: Utility  
 LEGAL REPRESENTATIVE: APPLICATION  
 SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH  
 AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 17  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 14253

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 21 OF 25 USPATFULL on STN  
 ACCESSION NUMBER: 2003:65344 USPATFULL  
 TITLE: Compositions and methods for the therapy, diagnosis and monitoring of breast cancer  
 INVENTOR(S): Fling, Steven P., Bainbridge Island, WA, UNITED STATES  
 Foy, Teresa M., Federal Way, WA, UNITED STATES  
 Clapper, Jonathan D., Seattle, WA, UNITED STATES  
 Wang, Aijun, Issaquah, WA, UNITED STATES  
 Johnson, Jeffrey C., Des Moines, WA, UNITED STATES  
 McNeill, Patricia D., Federal Way, WA, UNITED STATES  
 Sutherland, R. Alec, Bothell, WA, UNITED STATES  
 PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104  
 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003045468	A1	20030306	<--
APPLICATION INFO.:	US 2002-42945	A1	20020108 (10)	
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-8045, filed on 8 Dec 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-757417, filed on 8 Jan 2001, PENDING Continuation-in-part of Ser. No. US 2000-580376, filed on 26 May 2000, PENDING			

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1999-137048P	19990601 (60)	<--
	US 1999-136528P	19990528 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	32 Drawing Page(s)		
LINE COUNT:	3064		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	Compositions and methods for the therapy, diagnosis and monitoring of breast cancer are disclosed. Compositions may comprise one or more mammoglobin epitopes, or antibodies or T cells thereto, and may be used,		

- for example, for the prevention and treatment of breast cancer.
- Diagnostic methods based on detecting the presence of mammaglobin epitopes, or antibodies or T cells thereto, in a sample are also provided. Also provided are methods for detecting RNA encoding mammaglobin in patient blood or fractions thereof. These methods may be used to detect and/or monitor the progression of breast cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 22 OF 25 USPATFULL on STN

ACCESSION NUMBER: 2002:272801 USPATFULL

TITLE: Compositions and methods for the therapy and diagnosis of colon cancer

INVENTOR(S): Stolk, John A., Bothell, WA, UNITED STATES

Xu, Jiangchun, Bellevue, WA, UNITED STATES

Chenault, Ruth A., Seattle, WA, UNITED STATES

Meagher, Madeleine Joy, Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

US 2002150922	A1	20021017	<--
US 2001-998598	A1	20011116 (9)	

NUMBER	DATE
--------	------

US 2001-304037P	20010710 (60)	<--
US 2001-279670P	20010328 (60)	<--
US 2001-267011P	20010206 (60)	<--
US 2000-252222P	20001120 (60)	<--

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 17

EXEMPLARY CLAIM: 1

LINE COUNT: 9233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 23 OF 25 USPATFULL on STN

ACCESSION NUMBER: 2002:243051 USPATFULL

TITLE: Compositions and methods for the therapy and diagnosis of ovarian cancer

INVENTOR(S): Algata, Paul A., Issaquah, WA, UNITED STATES

Jones, Robert, Seattle, WA, UNITED STATES

Harlocker, Susan L., Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002132237	A1	20020919	<--
APPLICATION INFO.:	US 2001-867701	A1	20010529 (9)	
	NUMBER	DATE		
PRIORITY INFORMATION:	US 2000-207484P	20000526 (60)		<--
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092			
NUMBER OF CLAIMS:	11			
EXEMPLARY CLAIM:	1			
LINE COUNT:	25718			
CAS INDEXING IS AVAILABLE FOR THIS PATENT.				
AB	Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 24 OF 25 USPATFULL on STN  
 ACCESSION NUMBER: 2002:242791 USPATFULL  
 TITLE: Compositions and methods for the therapy and diagnosis of colon cancer  
 INVENTOR(S): King, Gordon E., Shoreline, WA, UNITED STATES  
 Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
 Xu, Jiangchun, Bellevue, WA, UNITED STATES  
 Secrist, Heather, Seattle, WA, UNITED STATES  
 PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002131971	A1	20020919	<--
APPLICATION INFO.:	US 2001-33528	A1	20011226 (10)	
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001, PENDING			

	NUMBER	DATE		
PRIORITY INFORMATION:	US 2001-302051P	20010629 (60)		<--
	US 2001-279763P	20010328 (60)		<--
	US 2000-223283P	20000803 (60)		<--
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092			
NUMBER OF CLAIMS:	17			
EXEMPLARY CLAIM:	1			
LINE COUNT:	8083			
CAS INDEXING IS AVAILABLE FOR THIS PATENT.				
AB	Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions			

comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 25 OF 25 USPATFULL on STN

ACCESSION NUMBER: 2002:157612 USPATFULL

TITLE: Compositions and methods for the therapy, diagnosis and monitoring of breast cancer

INVENTOR(S): Fanger, Gary R., Mill Creek, WA, UNITED STATES  
Foy, Teresa M., Federal Way, WA, UNITED STATES  
Houghton, Raymond L., Bothell, WA, UNITED STATES  
Reed, Steven G., Bellevue, WA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 2002082216	A1	20020627	<--
---------------------	---------------	----	----------	-----

APPLICATION INFO.:	US 2001-757417	A1	20010108 (9)	
--------------------	----------------	----	--------------	--

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-580376, filed on 26 May 2000, PENDING			
-----------------------	--	--	--	--

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 73

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 32 Drawing Page(s)

LINE COUNT: 2697

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy, diagnosis and monitoring of breast cancer are disclosed. Compositions may comprise one or more mammaglobin epitopes, or antibodies or T cells thereto, and may be used, for example, for the prevention and treatment of breast cancer. Diagnostic methods based on detecting the presence of mammaglobin epitopes, or antibodies or T cells thereto, in a sample are also provided. Also provided are methods for detecting RNA encoding mammaglobin in patient blood or fractions thereof. These methods may be used to detect and/or monitor the progression of breast cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs ind 130 1-1

L30 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:394694 HCAPLUS  
DOCUMENT NUMBER: 142:407215  
TITLE: Enrichment and tagging of **glycosylated proteins**  
INVENTOR(S): Robotti, Karla M.  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 11 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005095647	A1	20050505	US 2003-699449	20031031
PRIORITY APPLN. INFO.:			US 2003-699449	20031031

AB A method useful in the anal. of **glycosylated proteins**, in which a mixture containing **glycosylated proteins** and **unglycosylated proteins** is contacted with a resin that includes a nucleophile bound to a solid support via a linker. The contacting is performed under conditions sufficient to result in removal of the glycosyl group from the **glycosylated proteins** and to concomitantly result in the **deglycosylated proteins** covalently bound to the solid support. The **deglycosylated proteins** bound to the solid support may be rinsed to remove proteins that are not covalently bound to the solid support. The **deglycosylated proteins** are released from the solid support and may be subjected to further purification and/or anal.

IC ICM G01N033-53  
ICS C12P021-06

INCL 435007100; 435068100; 436092000

CC 9-16 (Biochemical Methods)

ST enrichment tagging **glycosylated protein**

IT Gel electrophoresis

HPLC

Solid phase synthesis supports

Test kits

(enrichment and tagging of **glycosylated proteins**)

IT Proteins

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(ligand-binding; enrichment and tagging of **glycosylated proteins**)

IT 107-95-9,  $\beta$ -Alanine

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(enrichment and tagging of **glycosylated proteins**)